Hepatic histopathology and postoperative outcome after preoperative chemotherapy for Chinese patients with colorectal liver metastases

Table 1 Clinical and pathological features of patients (n = 106) n (%)

Variable	Patients
Sex
Female	56 (52.8)
Male	50 (47.2)
Site of primary tumor
Colon	55 (51.9)
Rectum	51 (48.1)
Hepatic metastases
Median	3
Solitary	61 (57.5)
Multiple	45 (42.5)
Metastases type
Synchronous	44 (41.5)
Metachronous	62 (58.5)
Extent of hepatic resection
Minor (1-2 segment)	81 (76.4)
Major (≥ 3 segment or hemihepatectomy)	25 (23.6)

Median age of patients is 60 yr.

Table 2 Patient clinicopathological characteristics stratified by whether they received chemotherapy n (%)

Variable	Patients (n = 106)	Chemotherapy (n = 53)	Oxaliplatin (n = 33)	Irinotecan (n = 9)	HAI (n = 11)	P value
Mean age, yr	60	59.8	56.9	56.9	54.2	0.26
Gender
Female	56 (52.8)	29 (54.7)	16 (48.5)	5 (55.6)	6 (54.5)	0.95
Male	50 (47.2)	24 (45.3)	17 (51.5)	4 (44.4)	5 (45.5)
Site of primary tumor
Colon	55 (51.9)	28 (52.8)	16 (48.5)	5 (55.6)	6 (54.5)	0.97
Rectum	51 (48.1)	25 (47.2)	17 (51.5)	4 (44.1)	5 (45.5)
Timing of hepatic metastases
Synchronous	44( 41.5)	19 (35.8)	20 (60.6)	2 (22.2)	3 (27.3)	0.05
Metachronous	62 (58.5)	34 (64.2)	13 (39.4)	7 (77.8)	8 (72.7)
Surgery type
Minor (1-2 segment)	81 (76.4)	42 (79.2)	24(72.7)	9 (100)	6 (54.5)	0.10
Major (≥ 3 segment or hemihepatectomy)	25 (23.6)	11 (20.8)	9 (27.3)	0 (0)	5 (45.5)
No. of hepatic CRM
Single	61 (57.5)	34 (64.2)	17 (51.5)	6 (66.7)	4 (36.4)	0.29
Multiple	45 (42.5)	19 (35.8)	16 (48.5)	3 (33.3)	7 (63.6)
Largest hepatic CRM tumor size, cm	10.4	4.87	4.55	4.73	4.05	0.87
Median estimated blood loss, mL	200	400	350	600	300	0.90
Duration of chemotherapy, wk (median)	4	0	4.8	4.1	0	< 0.0001
Postoperative complication
Yes	20 (18.9)	7 (13.2)	9 (27.3)	0 (0)	4 (36.4)	0.07
No	86 (81.1)	46 (86.8)	24 (72.7)	9 (100)	7 (63.6)

CRM: Colorectal metastases; HAI: Hepatic artery infusion.

Table 3 Liver injury characteristics stratified by preoperative therapy n (%)

Regimen	Liver toxicity (n = 51)			Steatosis > 30% (n = 16)			Sinusoidal dilation (n =31)			Steatohepatitis (n = 20)
	Yes	No	1P value	Yes	No	1P value	Yes	No	1P value	Yes	No	1P value
No CTx	19 (35.8)	34 (64.2)		5 (9.4)	48 (90.6)		11 (20.8)	42 (79.2)		6 (11.3)	47 (88.7)
Oxaliplatin	19 (57.6)	14 (42.4)	0.04	5 (15.2)	28 (84.8)	NS	14 (42.4)	19 (57.6)	0.03	7 (21.2)	26 (78.8)	NS
Irinotecan	5 (55.6)	4 (44.4)	NS	2 (22.2)	7 (77.8)	NS	1 (11.1)	8 (88.9)	NS	3 (33.3)	6 (66.7)	0.08
HAI	8 (72.7)	3 (27.3)	0.02	4 (36.4)	7 (63.6)	0.02	5 (45.5)	6 (54.5)	0.08	4 (36.4)	7 (63.6)	0.03

¹Presence of liver injury characteristic; each chemotherapy group vs no chemotherapy. CTx: Chemotherapy; NS: Not significant; HAI: Hepatic artery infusion.